The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 11 08 2018
revised: 20 12 2018
accepted: 27 01 2019
entrez: 11 3 2019
pubmed: 11 3 2019
medline: 10 7 2019
Statut: ppublish

Résumé

To investigate the impact of variant urothelial carcinoma of the bladder (UCB) histologies on extra nodal extension (ENE) and survival in lymph node (LN) positive bladder cancer patients undergoing radical cystectomy (RC). We meticulously reviewed all bladder specimens for presence of variant UCB histologies and LN specimen for presence and extent of ENE in 517 UCB patients treated with RC. Descriptive statistics, the Kaplan Meier method and multivariable Cox regression models evaluated the association between variant UCB histology, ENE and survival metrics including disease recurrence-free, cancer-specific, and overall survival, respectively. Overall, 138 patients had LN metastasis (27%), with a median number of 15 (IQR 9; 18) LNs removed. Among LN positive patients, 43 (31%) had ENE with a median length of 10 mm. Variant histology was present in 96 patients (18.6%) with squamous cell (12.0%) and sarcomatoid (2.5%) differentiation being the most common. In all patients, the presence of variant histology was neither associated with presence of LN metastasis nor ENE (all p-values = n.s.). In Kaplan-Meier analyses the presence of LN metastases and ENE in LN positive patients was significantly associated with disease recurrence and cancer-specific mortality, respectively (all p < 0.001). The presence of variant histology did not influence these outcomes (p = n.s.). In multivariable analyses, adjusted for standard UCB prognosticators, ENE, but not variant histology, independently predicted disease recurrence-free (hazard ratio (HR) 3.88, 95% confidence intervall (CI) 2.24-6.71, p < 0.001), cancer-specific (HR 4.60; 95% CI, 2.57-8.23, p < 0.001), and overall survival (HR 3.51; 95% CI, 2.10-5.86, p < 0.001). Variant UCB histologies do not seem to increase the incidence of LN metastasis or ENE. This study confirms ENE being a powerful predictor for outcomes in node positive UCB patients - regardless of variant histological differentiation. Our findings warrant validation in larger cohort setting.

Identifiants

pubmed: 30851902
pii: S0960-7404(18)30311-6
doi: 10.1016/j.suronc.2019.01.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-213

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Phillip Marks (P)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Philipp Gild (P)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Armin Soave (A)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Florian Janisch (F)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Sarah Minner (S)

University Medical Center Hamburg-Eppendorf, Department of Pathology, Hamburg, Germany.

Oliver Engel (O)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Malte W Vetterlein (MW)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Shahrokh F Shariat (SF)

Medical University Vienna, Department of Urology, Vienna, Austria.

Guido Sauter (G)

University Medical Center Hamburg-Eppendorf, Department of Pathology, Hamburg, Germany.

Roland Dahlem (R)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Margit Fisch (M)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany.

Michael Rink (M)

University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany. Electronic address: m.rink@uke.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH